UNSPSC 51322101: Crilvastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C14H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D2B8XWK36K, more generally known as crilvastatin. European Medicines Agency schedules crilvastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06819MIG. The term CRILVASTATIN is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 5, no. 3 1991, list 31. Most nations schedule crilvastatin under HS 29337900 and SITC 51561.

As of Q4 2014, CRILVASTATIN remains the US FDA Preferred Term for this commodity. Crilvastatin bears US NLM identifiers UMLS ID C0217468 and NCI Concept Code C90865. SMILES: CC1CC(CC(C1)(C)C)OC(=O)C2CCC(=O)N2.

UNSPSC 51322101 Crilvastatin, a Commodity code, covers pharmaceutical products supplied to state and local government health and safety agencies. Recent solicitations show state and local buyers procuring emergency medications, generic pharmaceuticals, and over-the-counter products for fire rescue services, pharmacy benefit programs, and multi-agency healthcare networks. The scope spans both acute-care emergency medications (epinephrine, adenosine, labetalol, diltiazem) and broader generic pharmaceutical catalogs distributed across state healthcare systems and cooperative purchasing alliances. Issuing bodies include city fire departments (Tampa Fire Rescue), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across participating jurisdictions including Oregon). The work involves direct supply agreements with manufacturers, wholesaler coordination, product compliance documentation (Good Manufacturing Practices, Drug Supply Chain Security Act, FDA registration), Safety Data Sheets, and expiration-date management.

Recent activity concentrates in the South (Florida, Texas) and Upper Midwest (Minnesota). The City of Tampa's Purchasing Department posted an IFB (Bid No. 26-P-00188) on April 24, 2026, with a due date of April 8, 2026, soliciting 370 units of Labetalol, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem for Tampa Fire Rescue at an estimated contract value of $40,000, with a Small Local Business Enterprise bid discount available. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP (S1070000015802) posted January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across state and local government facilities through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with awards effective July 1, 2026, and evaluation weighted heavily toward price competitiveness (75 percent). The Texas HHS Commission issued a Request for Information (RFI No. HHS0017013) on April 3, 2026, to explore direct-to-manufacturer prescription programs and vendor capabilities for implementing a Therapeutic Pharmacy Initiative outside traditional PBM and GPO channels, signaling potential future procurement activity in the state pharmacy benefit space.